Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The objective of the trial is to compare disease-free survival between adjuvant XELOX alone
vs XELOX with concurrent capecitabine and radiotherapy in curatively resected gastric cancer
patients with D2 dissection.